421 related articles for article (PubMed ID: 33217967)
1. Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer.
Santha S; Ling X; Aljahdali IAM; Rasam SS; Wang X; Liao J; Wang J; Fountzilas C; Li Q; Qu J; Li F
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33217967
[TBL] [Abstract][Full Text] [Related]
2. Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
Thangaiyan R; Aljahdali IA; Lent-Moore KY; Liao J; Ling X; Li F
Am J Transl Res; 2021; 13(7):7458-7474. PubMed ID: 34377229
[TBL] [Abstract][Full Text] [Related]
3. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.
Ling X; Wu W; Aljahdali IAM; Liao J; Santha S; Fountzilas C; Boland PM; Li F
Clin Transl Med; 2022 May; 12(5):e881. PubMed ID: 35604033
[TBL] [Abstract][Full Text] [Related]
4. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
[TBL] [Abstract][Full Text] [Related]
5. Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition.
Rabi T; Li F
Am J Cancer Res; 2018; 8(11):2267-2283. PubMed ID: 30555743
[TBL] [Abstract][Full Text] [Related]
6. Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
Li F
Am J Cancer Res; 2014; 4(3):304-11. PubMed ID: 24959385
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration.
Zhao J; Ling X; Cao S; Liu X; Wan S; Jiang T; Li F
Mol Pharm; 2014 Feb; 11(2):457-67. PubMed ID: 24329001
[TBL] [Abstract][Full Text] [Related]
8. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
Ling X; Wu W; Fan C; Xu C; Liao J; Rich LJ; Huang RY; Repasky EA; Wang X; Li F
J Exp Clin Cancer Res; 2018 Oct; 37(1):240. PubMed ID: 30285798
[TBL] [Abstract][Full Text] [Related]
9. An intravenous (i.v.) route-compatible formulation of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, improves FL118 antitumor efficacy and therapeutic index (TI).
Ling X; Li F
Am J Transl Res; 2013; 5(2):139-54. PubMed ID: 23573360
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?
Li F; Ling X; Harris DL; Liao J; Wang Y; Westover D; Jiang G; Xu B; Boland PM; Jin C
Am J Cancer Res; 2017; 7(2):370-382. PubMed ID: 28337384
[TBL] [Abstract][Full Text] [Related]
11. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.
Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X
J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
Smolensky D; Rathore K; Cekanova M
BMC Cancer; 2015 Nov; 15():927. PubMed ID: 26597249
[TBL] [Abstract][Full Text] [Related]
13. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.
Ling X; Liu X; Zhong K; Smith N; Prey J; Li F
Am J Transl Res; 2015; 7(10):1765-81. PubMed ID: 26692923
[TBL] [Abstract][Full Text] [Related]
14. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.
Ling X; Xu C; Fan C; Zhong K; Li F; Wang X
Cancer Res; 2014 Dec; 74(24):7487-97. PubMed ID: 25512388
[TBL] [Abstract][Full Text] [Related]
15. Akt mediated ROS-dependent selective targeting of mutant KRAS tumors.
Iskandar K; Rezlan M; Pervaiz S
Free Radic Biol Med; 2014 Oct; 75 Suppl 1():S13. PubMed ID: 26461287
[TBL] [Abstract][Full Text] [Related]
16. FL118, a novel survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties.
Wang J; Liu Z; Zhang D; Liu R; Lin Q; Liu J; Yang Z; Ma Q; Sun D; Zhou X; Jiang G
Am J Transl Res; 2017; 9(8):3676-3686. PubMed ID: 28861158
[TBL] [Abstract][Full Text] [Related]
17. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
18. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin resistance by induction of aldo-keto reductase family 1 member C2 in human bladder cancer cells.
Shirato A; Kikugawa T; Miura N; Tanji N; Takemori N; Higashiyama S; Yokoyama M
Oncol Lett; 2014 Mar; 7(3):674-678. PubMed ID: 24527071
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
Iskandar K; Rezlan M; Yadav SK; Foo CH; Sethi G; Qiang Y; Bellot GL; Pervaiz S
Antioxid Redox Signal; 2016 May; 24(14):781-94. PubMed ID: 26714745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
